


PHARMACEUTICAL 2022



ANAPTYSBIO INC Rank 41 of 475








RealRate

PHARMACEUTICAL 2022





The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of ANAPTYSBIO INC is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 414% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	553,876
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,099
Liabilities, Non-Current	0
Other Assets	86,911
Other Compr. Net Income	-418
Other Expenses	0
Other Liabilities	0
Other Net Income	-982
Property and Equipment	2,283
Research and Development	98,496
Revenues	63,175
Selling, General and Administrative Expense	21,493

Output Variable	Value in 1000 USD
Assets	643,070
Liabilities	16,099
Expenses	119,989
Stockholders Equity	626,971
Net Income	-57,796
Comprehensive Net Income	-58,005
Economic Capital Ratio	138%

